Microbiome Testing Platform Tiny Health Raises $33M to Expand Clinical Research and AI Development
Tiny Health secured $33 million in Series B funding, bringing total equity capitalization to $46 million, as the company transitions from direct-to-consumer services toward enterprise clinical diagnostics and data infrastructure. The company has achieved over $10 million in annual revenue with year-over-year growth exceeding 100 percent, driven primarily by its business-to-business enterprise division and expanding adult microbiome profiling services. Funding will accelerate clinical research, expand its AI system trained on nearly 200,000 microbiome profiles, and establish a $5 million research program providing academic investigators access to its sequencing infrastructure and datasets.
Tiny Health has transitioned from a consumer-focused testing service into an enterprise diagnostic platform, with its business-to-business division demonstrating particularly strong traction. The company's revenue has crossed $10 million annually with growth rates exceeding 100 percent year-over-year, supported by expansion into adult microbiome profiling services alongside its original pediatric focus.
The funding will support multiple strategic initiatives: advancing clinical research through translational studies, developing proprietary artificial intelligence trained on nearly 200,000 microbiome profiles, and establishing an open-access research program worth $5 million that offers academic investigators access to the company's sequencing capabilities and data repositories.
The company's pivot toward clinical-grade diagnostics and data infrastructure could influence how microbiome testing becomes integrated into standard medical practice across age groups. By providing academic researchers access to its datasets and sequencing capabilities, Tiny Health may accelerate independent validation of microbiome-based diagnostics. However, the broader clinical impact depends on whether findings from expanded AI systems and research programs demonstrate actionable clinical utility in treating conditions related to immune and metabolic health.